Viking Therapeutics Q3 net loss more than doubles to $183.19 million
Bitget2026/10/28 20:12- Viking Therapeutics’ third-quarter 2026 net loss more than doubled year over year to $183.19 million due to higher operating expenses.
- Research and development expenses jumped 85% to $166.8 million, primarily due to increased clinical study and manufacturing costs.
- Quarter-end cash, cash equivalents and short-term investments totaled $960 million, including approximately $550 million in net financing proceeds.
- Oral VK2735 Phase 3 SUNRISE trials began; subcutaneous VK2735 Phase 3 VANQUISH studies remain on track for completion in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
